Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 1992 Oct;68(4):392-7.
doi: 10.1136/hrt.68.10.392.

Efficacy of flecainide, sotalol, and verapamil in the treatment of right ventricular tachycardia in patients without overt cardiac abnormality

J S Gill  1 , D Mehta, D E Ward, A J Camm
Affiliations
Comparative Study

Efficacy of flecainide, sotalol, and verapamil in the treatment of right ventricular tachycardia in patients without overt cardiac abnormality

J S Gill et al. Br Heart J. 1992 Oct.

Abstract

Objective: A comparison of the efficacy of verapamil, sotalol, and flecainide to suppress right ventricular tachycardia (VT) in patients with a clinically normal heart.

Design: Patients underwent treatment serially with verapamil (360 mg daily), sotalol (240 or 320 mg daily), and flecainide (200 or 300 mg daily), (the larger dose was for patients heavier than 80 kg) to suppress tachycardia. Each drug was given orally for five half lives before testing.

Patients: 23 patients with right VT associated with a clinically normal heart were studied.

Outcome measures: The effects of drug treatment were examined by the number of ventricular events on 24 hour Holter monitoring, and the ability of tachycardia to be induced by treadmill exercise testing (Bruce protocol) and programmed ventricular stimulation (Wellens protocol), compared with drug free baseline tests.

Setting: Patients were studied in a tertiary referral centre.

Results: All three drugs suppressed ventricular salvos (> 3, < 5 consecutive ventricular premature contractions) (p < 0.01) and VT (p < 0.05) on Holter monitoring and did not differ statistically in effect. Exercise induced VT was also suppressed by all three drugs (p < 0.01), and of these sotalol was the most effective although this was not statistically significant (14/23 inducible when drug free, 4/23 on flecainide, 2/23 on sotalol, 5/23 on verapamil). Sustained and non-sustained VT induced by programmed stimulation was also suppressed by the three drugs (p < 0.01) and again sotalol was the best of these though the differences did not achieve statistical significance (17/23 inducible when drug free, 4/17 on flecainide, 2/17 on sotalol, and 6/17 on verapamil). Proarrhythmic effects of drugs were found in a few patients. There was no difference in the efficacy of the drugs in patients with histological abnormalities of the myocardium when compared with those of normal histology.

Conclusions: Ventricular tachycardia associated with a clinically normal heart can be suppressed by flecainide, sotalol, or verapamil. In individual patients sotalol was the most frequently effective drug (effective in > 89% of patients) and is a suitable choice for first line treatment.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

  • [Should we treat asymptomatic premature ventricular contractions?].
    Forkmann M, Busch S. Forkmann M, et al. Herzschrittmacherther Elektrophysiol. 2023 Jun;34(2):131-135. doi: 10.1007/s00399-023-00934-7. Epub 2023 Mar 20. Herzschrittmacherther Elektrophysiol. 2023. PMID: 36941444 Review. German.
  • Clinical characteristics and catheter ablation of left ventricular outflow tract tachycardia.
    Dixit S, Marchlinski FE. Dixit S, et al. Curr Cardiol Rep. 2001 Jul;3(4):305-13. doi: 10.1007/s11886-001-0085-y. Curr Cardiol Rep. 2001. PMID: 11406089 Review.
  • [Premature ventricular contractions and tachycardia in a structurally normal heart : Idiopathic PVC and VT].
    Busch S, Eckardt L, Sommer P, Meyer C, Bonnemeier H, Thomas D, Neuberger HR, Tilz RR, Steven D, von Bary C, Kuniss M, Voss F, Estner HL. Busch S, et al. Herzschrittmacherther Elektrophysiol. 2019 Jun;30(2):212-224. doi: 10.1007/s00399-019-0607-1. Epub 2019 Feb 14. Herzschrittmacherther Elektrophysiol. 2019. PMID: 30767064 German.
  • The diagnosis and management of ventricular arrhythmias.
    Roberts-Thomson KC, Lau DH, Sanders P. Roberts-Thomson KC, et al. Nat Rev Cardiol. 2011 Jun;8(6):311-21. doi: 10.1038/nrcardio.2011.15. Epub 2011 Feb 22. Nat Rev Cardiol. 2011. PMID: 21343901 Review.
  • JCS/JHRS 2020 Guideline on Pharmacotherapy of Cardiac Arrhythmias.
    Ono K, Iwasaki YK, Akao M, Ikeda T, Ishii K, Inden Y, Kusano K, Kobayashi Y, Koretsune Y, Sasano T, Sumitomo N, Takahashi N, Niwano S, Hagiwara N, Hisatome I, Furukawa T, Honjo H, Maruyama T, Murakawa Y, Yasaka M, Watanabe E, Aiba T, Amino M, Itoh H, Ogawa H, Okumura Y, Aoki-Kamiya C, Kishihara J, Kodani E, Komatsu T, Sakamoto Y, Satomi K, Shiga T, Shinohara T, Suzuki A, Suzuki S, Sekiguchi Y, Nagase S, Hayami N, Harada M, Fujino T, Makiyama T, Maruyama M, Miake J, Muraji S, Murata H, Morita N, Yokoshiki H, Yoshioka K, Yodogawa K, Inoue H, Okumura K, Kimura T, Tsutsui H, Shimizu W; Japanese Circulation Society and; Japanese Heart Rhythm Society Joint Working Group. Ono K, et al. J Arrhythm. 2022 Oct 25;38(6):833-973. doi: 10.1002/joa3.12714. eCollection 2022 Dec. J Arrhythm. 2022. PMID: 36524037 Free PMC article. No abstract available.
See all "Cited by" articles

References

    1. Chest. 1986 Jun;89(6):790-4 - PubMed
    1. Pacing Clin Electrophysiol. 1989 Jun;12(6):977-89 - PubMed
    1. Circulation. 1986 Aug;74(2):270-80 - PubMed
    1. N Engl J Med. 1988 Jan 21;318(3):129-33 - PubMed
    1. Circulation. 1986 Jun;73(6):1111-8 - PubMed

Publication types

LinkOut - more resources